Core Viewpoint - Chengdu Dijiang, the controlling shareholder of Huason Pharmaceutical, has reduced its shareholding due to funding needs, but this change will not affect the company's control or ongoing operations [1][3]. Shareholding Changes - Before the recent changes, Chengdu Dijiang and its concerted parties held a total of 287,123,875 shares, accounting for 68.76% of the total share capital. After the reduction, they now hold 283,965,675 shares, which is 68.00% of the total [1][2]. - The reduction involved selling 948,400 shares through centralized bidding and 2,209,800 shares through block trading, totaling 3,158,200 shares sold [1][2]. Financial Performance - In 2024, Huason Pharmaceutical reported a revenue of 775 million yuan, a year-on-year increase of 12.04%. The net profit attributable to shareholders was approximately 76.73 million yuan, up 134.66% compared to the previous year [4][5]. - The net cash flow from operating activities was 161.77 million yuan, showing a decline of 26.25% year-on-year [4][5]. - Basic earnings per share increased to 0.1837 yuan, reflecting a growth of 134.61% [4][5]. Shareholding Structure - The shareholding structure indicates that Chengdu Dijiang holds 41.24% of the shares as unrestricted, while 17.34% are under restricted conditions. The total number of shares held by Chengdu Dijiang and its concerted parties has decreased from 290,472,175 shares (69.56%) to 283,965,675 shares (68.00%) [2][3].

Group 1 - Qianpu Investment recently conducted research on Huason Pharmaceutical, focusing on the re-development plans for key traditional Chinese medicine products [1] - Huason Pharmaceutical's major products, including Bawei Qilong Granules and Liuwai Anshen Capsules, are expected to receive national secondary protection status in 2024 [1] - The company primarily sells through public hospitals, with hospital sales accounting for approximately 70% of its market [1] - Huason Yinnuo has seven Class 1 innovative drug projects in development, with ORIC-1940 currently in clinical Ia/Ib phase studies [1] - The company has received a special medical food registration certificate for the TY005 project, and the production line for special medical foods will gradually release capacity [1] - A decrease in R&D investment is attributed to reduced capitalization project amounts and lower expenditures on development-stage projects compared to previous years [1] - The company has obtained registration approval for key traditional Chinese medicine products in Singapore, marking an important milestone for overseas product exports [1] - Huason Pharmaceutical is actively addressing price reduction risks from centralized procurement through a diversified development strategy, including the layout of special medical foods with strong consumer attributes [1] - The company anticipates generating a certain amount of Ib phase data next year, with ORIC-1940 showing good safety in preclinical studies [1] - ORIC-1940, as a RIPK1 inhibitor, can suppress necroptosis and apoptosis, reducing DMPs levels [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-052 重庆华森制药股份有限公司 关于控股股东及其一致行动人持股变动触及 1%整数 倍的公告 公司控股股东成都地方建筑机械化工程有限公司及其一致行动人游洪涛先生、 王瑛女士、上海添橙投资管理有限公司－添橙添利一号私募证券投资基金保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 本次减持与此前已披露的减持计划一致，减持数量在已披露的减持计划范围 内，不存在违反已披露的减持计划及相关承诺的情形。 本次变动是否存在 违反《证券法》《上 市公司收购管理办 法》等法律、行政法 规、部门规章、规范 性文件和本所业务 规则等规定的情况 是□ 否☑ 如是，请说明违规的具体情况、整改计划和处理措施。 5．被限制表决权的股份情况 按照《证券法》第六 十三条的规定，是否 存在不得行使表决 权的股份 是□ 否☑ 如是，请说明对应股份数量及占现有上市公司股本的比 例。 6．备查文件 1．中国证券登记结算有限责任公司持股变动明细 ☑ 2．相关书面承诺文件 □ 3．律师的书面 ...

Group 1: Company Performance and Product Development - The five key traditional Chinese medicine products have seen a revenue increase of 24.49% year-on-year in Q1 2025, with the total revenue for these products growing by 31.44% year-to-date [3][4] - The sales of Gan Zhi Bing Mei Pian increased by 38.84% during the reporting period, with a year-to-date growth of 54.36% [3] - The company has received national-level protection for two key products, extending their protection period by 7 years [2] Group 2: Market Strategy and Sales Channels - Approximately 70% of the company's sales occur within public hospitals, with ongoing efforts to expand into grassroots hospitals, private hospitals, retail pharmacies, and e-commerce platforms [4] - The company is actively developing its presence in the retail pharmacy sector and e-commerce to increase its market share outside of hospitals [4] Group 3: Research and Development - The company has integrated its R&D capabilities with Chengdu Aorui Pharmaceutical Co., gaining control over 7 innovative drug projects targeting various cancers and autoimmune diseases [5][6] - R&D expenditures decreased by 44.58% in 2024 compared to the previous year, primarily due to a reduction in capitalized project amounts [8][9] Group 4: International Expansion - The company has achieved significant milestones in international markets, including obtaining FDA approval for its production base and registering key products in Singapore [10] - The successful registration of products in Singapore marks a critical step in the company's strategy to expand its overseas product offerings [10] Group 5: Response to Market Challenges - The company is adapting to price reductions from centralized procurement by diversifying its product lines and enhancing its marketing strategies [11] - The focus remains on leveraging existing sales channels while exploring new growth opportunities in specialty foods and nutritional products [11]

Group 1: Company Performance and Financials - In 2024, the company achieved a revenue of 775 million CNY, an increase of 12.04% year-on-year, driven by strong growth in traditional Chinese medicine products, with five key products growing by 21.71% [7] - The sales revenue of Ganju Bingmei tablets increased by 29.97%, while the sales revenue of Liwei Anshen capsules grew by 23.38% [7] - In Q1 2025, the company reported a revenue of 239 million CNY, a year-on-year increase of 4.62%, with a slowdown attributed to reduced market demand compared to the previous year's flu outbreak [7] - The five key traditional Chinese medicine products saw a slight revenue increase of 0.93% in Q1 2025, with Liwei Anshen capsules growing by 32.10% and Tongxie Ning granules increasing by 80.24% [7] - The overall growth of state drug collection varieties during the reporting period was 28.71%, indicating strong market access and execution capabilities [7] Group 2: Product Development and Clinical Trials - ORIC-1940 is a novel RIPK1 inhibitor, currently in clinical trials for HLH, with expectations for data from Phase Ib trials to emerge next year [3][4] - The molecule has shown good safety in preclinical studies and aims to address the limitations of existing therapies in HLH treatment [3] - The company plans to explore additional indications for ORIC-1940, including adult secondary HLH and potentially primary HLH and pediatric HLH [5] - The company is actively pursuing overseas business development opportunities for ORIC-1940, although the success of these efforts remains uncertain [5] Group 3: Market Strategy and Future Outlook - The company maintains a commitment to investing in innovative drug development, with future expenses and plans contingent on actual project conditions [5] - The Southeast Asian market is viewed as a new international market for the company, with uncertain volume growth expectations [6] - The company is focused on optimizing its product structure and has successfully established a "333" pipeline layout, with new products expected to contribute to future revenue growth [7]

Group 1 - The controlling shareholder Chengdu Local Construction Machinery Engineering Co., Ltd. and its concerted parties have reduced their shareholding in Huason Pharmaceutical Co., Ltd. from 70.00% to 68.76% through various trading methods [1][2] - A total of 5,193,650 shares were reduced, representing a decrease of 1.24% of the company's total share capital [1][2] - The shareholding structure post-reduction shows that Chengdu Local Construction and its concerted parties now hold 287,123,875 shares [1][2] Group 2 - The reduction of shares was executed in compliance with previously disclosed plans, and the total number of shares reduced is within the limits set by the reduction plan [2][3] - The reduction occurred between January 24, 2025, and June 9, 2025, with specific details on the number of shares sold through block trades and centralized bidding [1][2] - The announcement confirms that the information provided is accurate and complete, with no misleading statements or significant omissions [1]

证券代码：002907 证券简称：华森制药 公告编号：2025-051 重庆华森制药股份有限公司 关于控股股东及其一致行动人持股变动触及 1%整数 倍的公告 公司控股股东成都地方建筑机械化工程有限公司及其一致行动人游洪涛先生、 王瑛女士、上海添橙投资管理有限公司－添橙添利一号私募证券投资基金保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 | 1．基本情况 | | | | | | --- | --- | --- | --- | --- | | 信息披露 | 成都地方建筑机械化工程有限公司（下称"成都地建"）、游 | | | | | 义务人 | 洪涛、王瑛、上海添橙投资管理有限公司－添橙添利一号私募 | | | | | | 证券投资基金（下称"添橙添利一号私募基金"） | | | | | | 成都地建地址：成都市郫都区安靖镇土地村 | | | | | | 游洪涛、王瑛住所：重庆市渝北区**** | | | | | 住所 | 添橙添利一号私募基金地址：上海市静安区南京西路 580 | | | 号 | | | 40 ...

Group 1: Research Basic Information - The research object is Huasen Pharmaceutical, belonging to the traditional Chinese medicine industry, and the reception time is June 9, 2025. The listed company's reception staff includes Zhou Zhiru, the representative of the securities affairs, and Long Jie, the commissioner of the securities affairs [17] Group 2: Detailed Research Institutions - The research institutions include Zhonggeng Fund (a fund management company) with researcher Li Niuniu, and Guojin Medicine (others) with researcher Wang Benben [18] Group 3: Proportion of Research Institutions - Fund management companies account for 50%, and others account for 50%, with 1 fund management company and 1 other institution [19] Group 4: Core Views - The five key Chinese patent medicines of the company maintained a good growth momentum in 2024 and Q1 2025, and the company focuses on their technology market promotion and access work, especially in non - grade public hospital channels [23] - The company's current sales terminal is mainly public hospitals, accounting for about 70%. It will actively layout the out - of - hospital market to increase its proportion [24] - In May 2025, Huasen Yinuo increased its stake in and controlled Aorui Pharmaceutical, integrating its R & D pipeline, team, and equipment. It now has 7 self - initiated Class 1.1 innovative drug R & D projects, with the most advanced one in clinical Ia/Ib phase [25] - The company's short - and medium - term R & D strategy focuses on product listing, and it has built a "333" pipeline pattern and multiple innovative drug R & D platforms [25][26]

Group 1: Financial Performance - The revenue of the five key traditional Chinese medicine products increased by 21.71% year-on-year in 2024, with 甘桔冰梅片 sales growing by 29.97% and 六味安神胶囊 by 23.38% [2] - In Q1 2025, the revenue of the five key products slightly increased by 0.93%, with 六味安神胶囊 growing by 32.10% and 痛泻宁颗粒 by 80.24% [2] Group 2: Market Strategy - The company focuses on expanding sales in non-grade public hospitals, including grassroots medical institutions, private hospitals, retail chains, and e-commerce platforms [3] - Currently, approximately 70% of sales are from public hospitals, with efforts to increase the share of sales from retail chains and e-commerce platforms [4] Group 3: R&D and Innovation - As of May 2025, the company has integrated with 成都奥睿药业, enhancing its R&D capabilities with 7 innovative drug projects in development targeting various cancers and autoimmune diseases [5] - The lead project, ORIC-1940, is in clinical phase Ia/Ib and aims to be the first innovative drug for secondary hemophagocytic lymphohistiocytosis in China [5] - The company has established a "three-three-three" pipeline structure and has applied for 35 patents, including 17 PCT patents, with 9 granted [6]

华森制药今日下跌8.23%，全天换手率18.14%，成交额11.61亿元，振幅13.67%。龙虎榜数据显示，机构 净买入4036.35万元，深股通净卖出274.01万元，营业部席位合计净卖出5714.39万元。 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 2473.63 | 409.07 | | 买二 | 华鑫证券有限责任公司上海光复路证券营业部 | 2431.10 | 2.44 | | 买三 | 深股通专用 | 2158.55 | 2432.56 | | 买四 | 中国国际金融股份有限公司上海分公司 | 2123.12 | 370.49 | | 买五 | 机构专用 | 2109.89 | 138.10 | | 卖一 | 联储证券股份有限公司上海松林路证券营业部 | 0.00 | 3771.84 | | 卖二 | 中国银河证券股份有限公司厦门嘉禾路证券营业部 | 55.04 | 3397.79 | | 卖三 | 深股通专用 | 2158.55 | 2432.56 | | ...